Previously, with kinome profiling we showed PDGFRβ, Src, ErbB family members, and HGFR are highly activated in pediatric low grade astrocytoma and ependymoma and were found to be potentially drugable targets in vitro.[5] However, more recent clinical trials analyzing single targeted therapy in pediatric brain tumors show disappointing results, possibly due to tumor escape mechanisms when specific targets are inhibited. This evidence concerns the gene PDGFRB and astrocytoma (excluding glioblastoma).